Vyant Bio Past Earnings Performance
Past criteria checks 0/6
Vyant Bio's earnings have been declining at an average annual rate of -17%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 9.8% per year.
Key information
-17.0%
Earnings growth rate
50.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -9.8% |
| Return on equity | -289.5% |
| Net Margin | -3,281.9% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Vyant Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -13 | 8 | 5 |
| 31 Mar 23 | 0 | -16 | 9 | 7 |
| 31 Dec 22 | 1 | -16 | 9 | 7 |
| 30 Sep 22 | 1 | -16 | 9 | 7 |
| 30 Jun 22 | 1 | -16 | 9 | 6 |
| 31 Mar 22 | 1 | -16 | 10 | 5 |
| 31 Dec 21 | 1 | -19 | 8 | 4 |
| 30 Sep 21 | 1 | -17 | 6 | 4 |
| 30 Jun 21 | 1 | -17 | 5 | 3 |
| 31 Mar 21 | 1 | -14 | 3 | 3 |
| 31 Dec 20 | 1 | -9 | 3 | 3 |
| 30 Sep 20 | 1 | -9 | 3 | 4 |
| 30 Jun 20 | 1 | -8 | 3 | 4 |
| 31 Mar 20 | 1 | -9 | 4 | 4 |
| 31 Dec 19 | 1 | -9 | 4 | 4 |
| 31 Dec 18 | 1 | -8 | 3 | 4 |
Quality Earnings: 1C80 is currently unprofitable.
Growing Profit Margin: 1C80 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1C80 is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.
Accelerating Growth: Unable to compare 1C80's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1C80 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 1C80 has a negative Return on Equity (-289.47%), as it is currently unprofitable.